Some single-nucleotide polymorphisms (SNPs) might be predictive of methotrexate (MTX) therapeutic outcome in rheumatoid arthritis (RA). The aim of this study was to determine whether SNPs in the methylenetetrahydrofolate reductase (MTHFR) gene are predictive of MTX response. Comparison was made using EULAR response criteria and according to the change of DAS28 (∆DAS28) after a 6-month MTX treatment in RA patient cohort. The two SNPs C677T (rs1801133) and A1298C (rs1801131) have been genotyped. A total of 120 patients were enrolled in the study, and all of them fulfilled the American College of Rheumatology 1987 RA criteria and are currently or previously taking MTX oral treatment, either as a monotherapy (n = 65) or in a combination with other disease-modifying antirheumatic drugs (n = 55). Genotyping was performed using qPCR allelic discrimination. We did not found any association of C677T and A1298C genotypes with MTX treatment inefficacy in dominant model (OR 1.23, 95 % CI 0.57-2.65, P = 0.697; and OR 0.98, 95 % CI 0.47-2.14, P = 1.0, respectively), or in recessive and codominant models. However, when ∆DAS28 after a 6-month therapy was used as a measure of treatment efficacy, the 677CT and 1298AC genotypes were found to be significantly associated with less favorable response to MTX (P = 0.025 and P = 0.043, respectively). In addition, even lower ∆DAS28 was determined for double-mutated 677CT-1298AC heterozygotes. It means that a synergistic effect of 677CT and 1298AC genotypes was observed. Nevertheless, the DAS28 baseline was lower here comparing to other genotypes. Unexpectedly, quite the opposite trend-i.e., better response to MTX-was found in genotypes 677CC-1298CC and 677TT-1298AA. It is an intriguing finding, because these double-mutated homozygotes are known for their low MTHFR-specific activity. Global significance was P = 0.013, η (2) = 0.160-i.e., large-size effect. Thus, our data show greater ability of 677CC-1298CC and 677TT-1298AA genotypes to respond to MTX treatment.

Faculty of Medicine and University Hospital 2nd Department of Internal Medicine Gastroenterology Charles University Prague Sokolska 581 500 05 Hradec Kralove Czech Republic

000      

00000naa a2200000 a 4500

001      

bmc16020989

003      

CZ-PrNML

005      

20180528162417.0

007      

ta

008      

160722s2015 gw f 000 0|eng||

009      

AR

024    7_

$a 10.1007/s00296-015-3219-z $2 doi

024    7_

$a 10.1007/s00296-015-3219-z $2 doi

035    __

$a (PubMed)25618758

040    __

$a ABA008 $b cze $d ABA008 $e AACR2

041    0_

$a eng

044    __

$a gw

100    1_

$a Soukup, Tomas $u Faculty of Medicine and University Hospital, 2nd Department of Internal Medicine - Gastroenterology, Charles University in Prague, Sokolska 581, 500 05, Hradec Kralove, Czech Republic, soukutom@seznam.cz.

245    14

$a The impact of C677T and A1298C MTHFR polymorphisms on methotrexate therapeutic response in East Bohemian region rheumatoid arthritis patients / $c T. Soukup, M. Dosedel, P. Pavek, J. Nekvindova, I. Barvik, I. Bubancova, P. Bradna, AA. Kubena, AF. Carazo, T. Veleta, J. Vlcek,

520    9_

$a Some single-nucleotide polymorphisms (SNPs) might be predictive of methotrexate (MTX) therapeutic outcome in rheumatoid arthritis (RA). The aim of this study was to determine whether SNPs in the methylenetetrahydrofolate reductase (MTHFR) gene are predictive of MTX response. Comparison was made using EULAR response criteria and according to the change of DAS28 (∆DAS28) after a 6-month MTX treatment in RA patient cohort. The two SNPs C677T (rs1801133) and A1298C (rs1801131) have been genotyped. A total of 120 patients were enrolled in the study, and all of them fulfilled the American College of Rheumatology 1987 RA criteria and are currently or previously taking MTX oral treatment, either as a monotherapy (n = 65) or in a combination with other disease-modifying antirheumatic drugs (n = 55). Genotyping was performed using qPCR allelic discrimination. We did not found any association of C677T and A1298C genotypes with MTX treatment inefficacy in dominant model (OR 1.23, 95 % CI 0.57-2.65, P = 0.697; and OR 0.98, 95 % CI 0.47-2.14, P = 1.0, respectively), or in recessive and codominant models. However, when ∆DAS28 after a 6-month therapy was used as a measure of treatment efficacy, the 677CT and 1298AC genotypes were found to be significantly associated with less favorable response to MTX (P = 0.025 and P = 0.043, respectively). In addition, even lower ∆DAS28 was determined for double-mutated 677CT-1298AC heterozygotes. It means that a synergistic effect of 677CT and 1298AC genotypes was observed. Nevertheless, the DAS28 baseline was lower here comparing to other genotypes. Unexpectedly, quite the opposite trend-i.e., better response to MTX-was found in genotypes 677CC-1298CC and 677TT-1298AA. It is an intriguing finding, because these double-mutated homozygotes are known for their low MTHFR-specific activity. Global significance was P = 0.013, η (2) = 0.160-i.e., large-size effect. Thus, our data show greater ability of 677CC-1298CC and 677TT-1298AA genotypes to respond to MTX treatment.

650    _2

$a dospělí $7 D000328

650    _2

$a senioři $7 D000368

650    _2

$a senioři nad 80 let $7 D000369

650    _2

$a antirevmatika $x škodlivé účinky $x metabolismus $x terapeutické užití $7 D018501

650    _2

$a revmatoidní artritida $x diagnóza $x farmakoterapie $x enzymologie $x genetika $7 D001172

650    _2

$a průřezové studie $7 D003430

650    _2

$a ženské pohlaví $7 D005260

650    _2

$a heterozygot $7 D006579

650    _2

$a homozygot $7 D006720

650    _2

$a lidé $7 D006801

650    _2

$a lineární modely $7 D016014

650    _2

$a logistické modely $7 D016015

650    _2

$a mužské pohlaví $7 D008297

650    _2

$a methotrexát $x škodlivé účinky $x metabolismus $x terapeutické užití $7 D008727

650    _2

$a methylentetrahydrofolátreduktasa (NADPH2) $x genetika $x metabolismus $7 D042965

650    _2

$a lidé středního věku $7 D008875

650    _2

$a odds ratio $7 D016017

650    _2

$a farmakogenetika $7 D010597

650    _2

$a fenotyp $7 D010641

650    _2

$a polymerázová řetězová reakce $7 D016133

650    12

$a jednonukleotidový polymorfismus $7 D020641

650    _2

$a prospektivní studie $7 D011446

650    _2

$a retrospektivní studie $7 D012189

650    _2

$a rizikové faktory $7 D012307

650    _2

$a výsledek terapie $7 D016896

651    _2

$a Česká republika $7 D018153

655    _2

$a časopisecké články $7 D016428

655    _2

$a práce podpořená grantem $7 D013485

700    1_

$a Dosedel, Martin

700    1_

$a Pavek, Petr

700    1_

$a Nekvindova, Jana

700    1_

$a Barvik, Ivan

700    1_

$a Bubancova, Iva

700    1_

$a Bradna, Petr

700    1_

$a Kubena, Ales Antonin

700    1_

$a Carazo, Alejandro Fernández

700    1_

$a Veleta, Tomáš $7 xx0224639

700    1_

$a Vlcek, Jiri

773    0_

$w MED00004228 $t Rheumatology international $x 1437-160X $g Roč. 35, č. 7 (2015), s. 1149-61

856    41

$u https://pubmed.ncbi.nlm.nih.gov/25618758 $y Pubmed

910    __

$a ABA008 $b sig $c sign $y a $z 0

990    __

$a 20160722 $b ABA008

991    __

$a 20180528162608 $b ABA008

999    __

$a ok $b bmc $g 1155659 $s 945517

BAS    __

$a 3

BAS    __

$a PreBMC

BMC    __

$a 2015 $b 35 $c 7 $d 1149-61 $e 20150125 $i 1437-160X $m Rheumatology international $n Rheumatol Int $x MED00004228

LZP    __

$a Pubmed-20160722